Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 23, 2006 Brian Lawler	No Slowing Novartis The Swiss pharmaceutical company shows strength in nearly all its divisions. Novartis looks like a good investment for risk-adverse investors searching for a large-cap pharma stock.
The Motley Fool July 17, 2007 Brian Lawler	Still Strong at Novartis For investors who are willing to filter the negative news and are patient enough to wait for recently launched branded compounds to help its top-line growth, Novartis is worth a look
The Motley Fool April 25, 2007 Brian Lawler	Nothing Wrong With Novartis Novartis releases first-quarter financial results. Investors, take note.
The Motley Fool October 21, 2008 Brian Orelli	Novartis Is Taking the Road Less Traveled Diversification should pay off for this pharma giant.
The Motley Fool April 22, 2008 Brian Lawler	No Earnings Holes for Novartis The drugmaker holds its own in Q1; all three of its major divisions experienced sales growth, even in the face of some tough comparisons to last year.
The Motley Fool July 14, 2005 Stephen D. Simpson	These Swiss Don't Miss Aside from a hiccup in margins, Novartis' drug business continues to shine. This pharma is a solid middle-of-the-road play with reasonable valuation, a solid pipeline, and a not-so-secret weapon in its Sandoz generics business.
The Motley Fool February 22, 2005 Brian Gorman	Novartis Embraces Generics The company is taking a different path from its branded pharmaceutical peers. The company's strategy may make its stock worth a closer look.
The Motley Fool January 29, 2009 Brian Orelli	Novartis: Diversification Isn't Good Enough Novartis has become a better diversified company, with acquisitions of vaccines specialist Chiron and 25% of eye-care specialist Alcon, but it's far from a cure all, as the fourth quarter showed.
The Motley Fool July 16, 2009 Brian Orelli	A Strong Dollar Can Hurt Novartis makes it through a hard quarter.
The Motley Fool July 28, 2011 Melly Alazraki	J&J or Novartis? Novartis' businesses are an investor's delight; J&J's improving but isn't there yet.
The Motley Fool September 20, 2005 Brian Gorman	Novartis Stays Focused New developments at the drug giant suggest the company is on track. Investors, take note.
The Motley Fool January 22, 2007 Brian Lawler	Another Busy Year in Store for Novartis Trying to place a value on Novartis is a tough thing to do now with so many important drugs awaiting regulatory review and its addiction to acquisitions and divestitures making financial comparisons between the years tough.
The Motley Fool October 23, 2009 Brian Orelli	Swine Flu Doesn't Need to Save Novartis The company is looking healthy all on its own.
The Motley Fool May 21, 2009 Brian Orelli	If You Can't Beat 'Em, Join 'Em: Pharma Goes Generic In the battle against generic rivals, it seems pharmaceutical companies would rather switch than fight. A pair of deals heralds Big Pharma's latest moves into the generic-drug world. See what Novartis and sanofi-aventis recently did.
Pharmaceutical Executive November 1, 2006 Joanna Breitstein	Back Page: The Case for Diversity Variety is the spice of life - and the future of Big Pharma.
The Motley Fool October 18, 2005 Stephen D. Simpson	More Good News From Novartis This Swiss drug giant continues to post steady growth. Investors, take note.
The Motley Fool June 6, 2008 Brian Lawler	Nothing Can Stop Novartis! Swiss pharmaceutical giant Novartis has bucketloads of cash, and apparently, it isn't afraid to use them.
The Motley Fool April 8, 2008 Brian Lawler	Novartis Sees More Growth Ahead Novartis makes one of the largest acquisitions in health-care history.
The Motley Fool January 19, 2006 Stephen D. Simpson	Novartis Marches On While reported profits are masked by some charges, this Swiss drug company is still delivering the goods. Throw in a solid pipeline and a reasonable valuation, and the stock could still be worth a look for new money in the pharmaceutical space.
The Motley Fool December 19, 2006 Brian Gorman	Novartis Cuts in Line at the Drugstore Consolidation in pharmacy benefits management may leave Novartis most resistant to pricing pressure. Investors, take note.
The Motley Fool July 16, 2010 Brian Orelli	A Positive Sign for Pharma Earnings Season Strong first-half results drove Novartis to increase its sales guidance for the year.
The Motley Fool November 26, 2007 Brian Lawler	Glaxo Goes Holiday Shopping The pharmaceutical giant snaps up another acquisition, privately held Reliant Pharmaceuticals, for $1.65 billion in cash, one of the largest pharma deals of the year.
The Motley Fool October 18, 2010 Brian Orelli	Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs.
The Motley Fool September 30, 2011 Brian Orelli	When You Need More Than Just a Low-Margin Business Teva Pharmaceuticals, arguably the largest generic-drug maker, can use economies of scale more easily than smaller companies like Watson Pharmaceuticals or Par Pharmaceutical, but it's still pushing further into branded drugs.
The Motley Fool November 3, 2010 Brian Orelli	Teva's New Drugs Pay Off The generic-drug maker keeps generating big profits.
The Motley Fool January 7, 2010 Brian Orelli	Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered.
The Motley Fool May 12, 2011 Brian Orelli	Teva's Mixed Bag Diversification sure helps.
The Motley Fool January 20, 2005 Stephen D. Simpson	Novartis Posts a Swiss Miss The Swiss drug giant has a strong pipeline, but moderate growth and high valuation suggest little room for error.
The Motley Fool April 14, 2005 Brian Gorman	Novartis Moves on Multiple Fronts Even with its investment in a potential blockbuster, Novartis remains remarkably diversified. Investors can rest assured, though, that the company's strategy won't leave it as vulnerable as other outfits.
The Motley Fool December 31, 2007 Brian Lawler	Big Pharma 2008 Forecast Roundup Investors, take a look at what 2008 has in store for big pharma.
The Motley Fool March 15, 2007 Brian Lawler	It's All Good for Drugmakers With the whole drug industry growing so strongly, those looking for a safe place to park their investing dollars would be smart to take a look at some of the largest generic drugmakers.
The Motley Fool October 26, 2011 Brian Orelli	Momenta Stopped. Again. Oh, no - an authorized generic gets launched.
The Motley Fool April 17, 2006 Brian Gorman	Novartis Presses on Biogenerics The company wins a court case that could accelerate U.S. regulations for biogenerics. Recent developments suggest Novartis' strategy may be close to paying off. Investors, take note.
The Motley Fool January 24, 2006 Stephen D. Simpson	Reddy, Set, Go! After a tough stretch, leading Indian pharmaceutical company Dr. Reddy's may be ready to move again. This is still a turnaround story, though, so investors unable or unwilling to assume above-average risk should probably steer clear.
The Motley Fool September 9, 2010 Jim Mueller	Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker.
The Motley Fool July 15, 2005 Stephen D. Simpson	Novartis' Over-the-Counter Tonic Novartis' latest purchase suggests a commitment to making itself a well-rounded pharma giant. Future margins may not be as high as they once were, but if the company can produce a lot more cash flow, investors won't mind a bit.
The Motley Fool November 19, 2009 Brian Orelli	Pfizer's Generic Growth, With a Side of Sashimi A move into Japan isn't a bad idea, but it isn't going to save the company either.
The Motley Fool September 30, 2008 Brian Lawler	Moody's Gets Moody With Drugmakers European pharmaceuticals get a negative rating from Moody's.
The Motley Fool August 6, 2011 Sean Williams	10 Large Caps to Rule Them All There's nothing generic about this company. For the inaugural large-cap pick, I think we should revisit pharma's most impervious pipeline, Teva Pharmaceuticals.
The Motley Fool February 21, 2008 Brian Orelli	Watson Gets Less Generic Branded sales were up while generics fell for the year, which made Watson Pharmaceutical a more balanced company.
The Motley Fool January 27, 2010 Brian Orelli	Nice, Novartis, Very Nice CEO Daniel Vasella leaves on a high note.
The Motley Fool April 4, 2007 Brian Lawler	Novartis Gets Nicked Novartis pulls one of its top-selling drugs from the market. Investors should come to expect drug delays or similar issues popping up from time to time when doing their analysis of large pharmas.
The Motley Fool August 12, 2010 Brian Orelli	Pfizer: Strengths, Weaknesses, Opportunities, Threats Knowing them all makes it easier to judge an investment.
The Motley Fool July 27, 2010 Brian Orelli	Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts.
The Motley Fool August 3, 2004 Jeff Hwang	Generics Pump Watson The firm's strong growth in generic drug sales eases its branded product pains. The stock is up more than 10%.
The Motley Fool September 11, 2007 Brian Lawler	Looking Forward at Pfizer With generic competition on the way for Pfizer's top drug, Lipitor, the company stepped up to the podium at the Bear Stearns Healthcare Conference this week to let investors know its plans.
The Motley Fool December 12, 2007 Brian Lawler	Patent Bill Is No Panacea A new bill that was meant to strengthen the patent and other intellectual-property rights of drugmakers doesn't do enough to encourage pharma innovation.
The Motley Fool September 24, 2008 Brian Lawler	Sanofi Gets the Golden Ring Sanofi-Aventis raises its bid and acquires Czech generic drugmaker Zentiva.
The Motley Fool March 23, 2010 Brian Orelli	No Patent! No Generics? Take Advantage of the Situation Enjoy it while it lasts, pharma.
The Motley Fool February 1, 2008 Brian Lawler	AstraZeneca's Trying to Get Healthier Big pharma AstraZeneca tries to get back on track by reducing costs.